Brought to you by 
Quest Diagnostics, Ciphergen develop new assays
15 Mar 2010
Executive Summary
Ciphergen and Quest Diagnostics will jointly develop and commercialize up to three assays from Ciphergen's pipeline over the next three years. Quest gets nonexclusive worldwide rights to sell resulting tests and an exclusive license for up to five years following launch for territories in which Quest has a significant presence. The partners will use Ciphergen's proprietary SELDI ProteinChip technology, a platform that provides researchers with tools to use in protein discovery, characterization, and identification, and predictive assay development.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Quest Diagnostics, Ciphergen develop new assays
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice